New Generic EpiPen Was Touted As A Lower Cost Option, But Its List Price Is The Same As One Already On Market

FDA Commissioner Scott Gottlieb said, “We cannot control commercial decisions on pricing, [but] importantly, we have found that having three or more generic competitors brings prices down more sharply than with only one or two generic competitors.”

from Kaiser Health News https://ift.tt/2SibtKK